Is β-cell failure in type 2 diabetes mellitus reversible?

International Journal of Diabetes in Developing Countries

Volumn 28, Issue 1, 2008, Pages 1-5

  Jain, Rashmi ^a   Kabadi, Udaya ^a   Kabadi, M ^b  

^a UNIVERSITY OF IOWA   (United States)

^b CARL T HAYDEN VA MEDICAL CENTER   (United States)

Author keywords

cell function; Obese; Type 2 diabetes; Weight loss

Indexed keywords

EID: 48849101830     PISSN: 09733930     EISSN: 19983832     Source Type: Journal    
DOI: 10.4103/0973-3930.41978     Document Type: Article

References (45)

1. Ward WK, Beard JC, Porte D. Clinical aspects of islet B cell function in non-insulin dependent diabetes mellitus. Diabetes Metab Rev 1986;2:297-313.
2. Leahy JL. Natural history of B-cell dysfunction in NIDDM. Diabetes Care 1991;13:992-1010.
3. Porte D. Beta cells in type 2 diabetes mellitus. Diabetes 1991;40:166-80.
4. Malaisse W. Metabolic signaling of insulin secretion. Diabetes Metab Rev 1996;4:145-59.
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes mellitus (UKPDS 33). Lancet 1998;12:837-53.
6. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes mellitus (UKPDS 34). Lancet 1998;12:854-65.
7. Luz L, De Fronzo RA. Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. Am J Physiol 1989;257:E241-6.
8. Groop LC, Ratheiser K, Luzi L, Melander A, Simonson DC, Petrides A, et al. Effect of sulphonylureas on glucose-stimulated insulin secretion in healthy and non-insulin dependent diabetes subjects: A dose response study. Acta Diabetol 1991;28:162-8.
9. Greenwood RH, Mahler RF, Hales CN. Improvement in insulin secretion in diabetes after diazoxide. Lancet 1976;1:444-7.
10. Bjork E, Berne C, Kampe O, Wibell L, Oskarsson P, Karlsson FA. Diazoxidetreatment at onset preserves residual insulin secretion in adults with autoimmune diabetes. Diabetes 1996;45:1427-30.
11. Guldstrand M, Grill V, Bjorklund A, Lins PE, Adamson U. Improved beta cell function after short-term treatment with diazoxide in obese subjects with type 2 diabetes. Diabetes Metab 2002;28:448-56.
12. Alexandrides TK, Skroubis G, Kalfarentzos F. Resolution of diabetes mellitus and metabolic syndrome following Roux-en-Y gastric bypass and a variant of biliopancreatic diversion in patients with morbid obesity. Obes Surg 2007;17:176-84.
13. Pories WJ, Swanson MS, MacDonald KG Jr, Long SB, Morris P, Brown BM, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995;222:339-52.
14. MacDonald KG Jr, Long SD, Swanson MS, Brown BM, Morris P, Dohm GL, et al. The gastric bypass operation reduces the progression and mortality in non-insulin-dependent diabetes mellitus. J Gastrointest Surg 1997;1:213-20.
15. Torquati A, Lutfi R, Abumrad N, Richards WO. Is Roux-en-Y gastric bypass surgery the most effective treatment for type 2 diabetes mellitus in morbidly obese patients? J Gastrointest Surg 2005;9:1112-8.
16. Zangeneh F, Arora PS, Dyck PJ, Bekris L, Lernmark A, Achenback SJ, et al. Effects of duration of type 2 diabetes mellitus on insulin secretion. Endocr Pract 2006;12:388-93.
17. Kabadi UM, Kabadi SU. Cumulative response: A reliable and accurate measurement of an integrated response during a dynamic test. Diabetes Res 1996;31:77-81.
18. Kabadi UM, Eisenstein AB. Impaired pancreatic α-cell response in hyperthyroidism. J Clin Endocrinol Metab 1980;51:478-82.
19. Clarke N, Sivitz W, Kabadi U. Product of fasting plasma glucose and fasting plasma insulin: A simple and reliable index of insulin sensitivity. Diabetes Res 2005;39:25-31.
20. Golay A, Guillet-Dauphine N, Fendel A, Juge C, Assal JP. The insulin-sparing effect of metformin in insulin-treated diabetic subjects. Diabetes Metab Rev 1995;11:S63-7.
21. Johnson JL, Wolf S, Kabadi U. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. Arch Intern Med 1996;156:259-64.
22. Riddle MC, Schneider J; the glimepiride combination group. Beginning insulin treatment of obese subjects with evening 70/30 insulin plus glimepiride versus insulin alone. Diabetes Care 1998;21:1052-7.
23. Chaudhuri A, Tomar R, Mohanty P, Szudzik E, Bandyopadhyay A, Arian M, et al. The combination of insulin and metformin in treatment of non-insulin dependent diabetes mellitus. Endocr Pract 1998;4:259-67.
24. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001;24:1226-32.
25. Wright A, Felix Burden AC, Paisey RB, Cull CA, Holman RR. UKPDS: Sulfonylurea inadequacy. Diabetes Care 2002;25:330-6.
26. Kabadi UM, Kabadi M. Comparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetes. Diabetes Res Clin Pract 2006;72:265-70.
27. Kabadi M, Kabadi U. Effects of glimepiride on insulin secretion and sensitivity in patients with recently diagnosed type 2 diabetes mellitus. Clin Ther 2004;26:63-9.
28. Weyer C, Hanson K, Bogardus C, Pratley RE. Long term changes in insulin action and insulin secretion associated with gain, loss, regain and maintenance of body weight. Diabetologia 2000;43:36-46.
29. Polyzogopoulou EV, Kalfarentzos F, Vagenakis AG, Alexandrides TK. Restoration of euglycemia and normal acute response to glucose in obese subjects with type 2 diabetes following bariatric surgery. Diabetes 2003;52:1098-103.
30. Camastra S, Manco M, Mari A, Baldi S, Gastaldelli A, Greco AV, et al. Beta-cell function in morbidly obese subjects during free living: Long term effects of weight loss. Diabetes 2005;54:2382-9.
31. Pories WJ, MacDonald KG Jr, Flickinger EG, Dohm GL, Sinha MK, Bakarat HA, et al. Is type II diabetes mellitus (NIDDM) a surgical disease? Ann Surg 1992;215:633-43.
32. Kabadi U, Kabadi M. Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus. Ann Pharmacother 2003;37:1572-6.
33. Ferrannini E, Gastaldelli A, Miyazaka Y, Matsuda M, Mari A, DeFronzo RA. B-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: A new analysis. J Clin Endocrinol Metab 2005;90:493-500.
34. Kabadi UM, Kabadi MU. Early insulin secretion: Influence of insulin sensitivity. Proceedings of the International Diabetes Federation; 2003. Abstract # 1730.
35. Long SD, O'Brien K, MacDonald KG Jr, Leggett-Frazier N, Swanson MS, Pories WJ, et al. Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes: A longitudinal international study. Diabetes Care 1994;17:372-5.
36. Mingrone G, DeGaetano A, Greco AV, Capristo E, Benedetti G, Castagneto M, et al. Reversibility of insulin resistance in obese diabetic patients: Role of plasma lipids. Diabetologia 1997;40:599-605.
37. Cowan GS Jr, Buffington CK. Significant changes in blood pressure, glucose and lipids with gastric bypass surgery. World J Surg 1998;22:987-92.
38. Buffington CK, Cowan GS Jr. Gastric bypass in the treatment of diabetes, hypertension and lipid/lipoprotein abnormalities of the morbidly obese. In Update: Surgery for the Morbidly Obese Patient. Deitel M, Cowan GS Jr, editors. Toronto: FD-Communications; 2000. p. 435-49.
39. UK Prospective Diabetes Study (UKPDS) Group. UK Prospective Diabetes Study 16: Overview of 6 years' therapy of type II diabetes: A progressive disease. Diabetes 1995;44:1249-58.
40. Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: Preclinical biology and mechanisms of action. Diabetes Care 2007;30:1335-43.
41. Kabadi, UM. United Kingdom prospective diabetes study: A different perspective. Endocr Prac 2002;8:61.
42. Kabadi U. Beta cell failure in type 2 diabetes mellitus is reversible. Proceedings of the ADA Scientific Sessions; 2006. Abstract #.
43. Narita R, Toshimori H, Nakazato M, Kuribayashi T, Toshimori T, Kawabata K, et al. Islet amyloid polypeptide (IAPP) and pancreatic islet amyloid deposition in diabetic and non-diabetic patients. Diabetes Res Clin Pract 1992;15:3-14.
44. Hayden MR. Islet amyloid and fibrosis in the cardiometabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr 2007;1:70-5.
45. Kabadi UM. DCCT: Medical and economical message. Exp Clin Endo Diabetes 1999;10:S24-9.